In the DEFINE-HF double-blind, randomized, placebo-controlled clinical trial of patients with HFrEF, patients treated with dapagliflozin did not experience statistically significant changes in ApoM compared to placebo. The gene discussed is APOM; the disease is hydrops fetalis.